Drug Profile


Alternative Names: BSI-201; SAR-240550

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator BiPar Sciences
  • Developer BiPar Sciences; National Cancer Institute (USA); Sanofi
  • Class Antineoplastics; Benzamides; Iodobenzenes; Nitro compounds; Small molecules
  • Mechanism of Action Cell cycle inhibitors; H2AFX protein stimulants; Tumour protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Breast cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Brain metastases; Breast cancer; Fallopian tube cancer; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Uterine cancer

Most Recent Events

  • 01 Jun 2015 Sanofi completes a phase I/II trial in Glioblastoma in USA (NCT00687765)
  • 01 Apr 2014 Sanofi completes a phase I trial in Solid tumours in USA (NCT01455532)
  • 02 Jul 2013 Drug classes Iodobenzenes, Nitro-compounds added.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top